Visszavonva2. fázis
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
A legfontosabb adatok
- Ki végzi
- John M. Buatti
- Hol
- Iowa City (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Visszavonva
- Fázis
- 2. fázis
- Kezdés
- 2019. máj. 15.
- Várható befejezés
- 2026. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó
- A vizsgált kezelések
- External beam radiation therapy
- A regiszteradat frissítve
- 2020. szeptember 9.
- Miért állt le
- Not funded
Ki vehet részt
- Életkor
- 18 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 25 feltétel megnézéseKevesebb
Ki vehet részt
- Ability to understand and willingness to provide informed consent
- Newly diagnosed, histologically-confirmed supratentorial WHO grade IV gliomas including glioblastoma (all variants) and gliosarcoma
- Patients must be 18 years of age or older.≥
- Karnofsky performance status ≥ 70
- Minimal life expectancy of 12 weeks
- Maximal contiguous volume of tumor based on high b-value diffusion MRI and perfusion MRI < 1/3 volume of brain
- Patients must be treated within 6 weeks of most recent resection; Within 21 days of radiation fraction 1, the following blood test parameters must be met:
- Hemoglobin ≥ 10 g/dL (transfusion is acceptable)
- absolute neutrophils ≥ 1500/mm3
- platelet count ≥ 100,000/mm3
- total bilirubin ≤ 2 x upper limit of normal (ULN) (unless elevated bilirubin is related to Gilbert syndrome)
- ALT and AST ≤ 5 x ULN
- serum creatinine ≤ 2.0 mg/dL
Ki nem vehet részt
- Recurrent glioma, or tumor involving the brainstem or cerebellum. Prior low-grade glioma without prior RT, now with malignant progression are eligible
- Prior use of Gliadel wafers or any other intratumoral or intracavitary treatment is not permitted. Prior chemotherapy for a different cancer is allowable if interval since last treatment cycle completion is >3 years
- Evidence of severe concurrent disease requiring treatment
- Patients treated with previous cranial or head/neck radiotherapy leading to significant radiation field overlap
- Pregnant women are excluded from this study because ionizing radiation is a known teratogen, and temozolomide is a Class D agent with the potential for teratogenic or abortifacient effects
- Nursing mothers declining to discontinue breastfeeding are excluded because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with temozolomide
- Evidence of CSF dissemination (positive CSF cytology for malignancy or MRI findings consistent with CSF dissemination)
- Multifocal disease (>1 lobe of involvement) of discontiguous, contrast enhancing disease as seen on conventional MRI
- Known active malignancy as determined by treating medical and radiation oncologist
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection requiring inpatient hospitalization or delay treatment, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements or compromise subject safety
- Patients unable to undergo MRI exams
- Patients with reproductive potential declining to use an effective contraceptive method during treatment are excluded from this study
Helyszínek itt: Egyesült Államok
- University of Iowa Department of Radiation OncologyIowa City, Egyesült Államok
A vizsgálatról
Mit akar kideríteni a vizsgálat
This clinical trial increases radiation to areas of the brain considered to be at risk for cancer. The at-risk areas are identified by a biological MRI scan. The study will look at side effects of the radiation and overall survival.
A vizsgálat csoportja
- Radiation TherapyA vizsgált kezelés
External beam radiation therapy delivered to target volume.
Kezelés: External beam radiation therapy
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Phase II Study of High Dose Radiotherapy and Concurrent Temozolomide Using Biologically-based Target Volume Definition in Patients With Newly Diagnosed Glioblastoma
- A regiszteradat frissítve
- 2020. szeptember 9.